We were delighted to catch up with Dr Susan Samson (Mayo Clinic, Jacksonville, FL, US) to discuss the one-year outcomes of oral octreotide capsule use in patients with acromegaly.
‘One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly.‘ (PRESENTATION NUMBER: OR14-3) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
Questions
- What have been the major challenges of injectable therapies for people living with acromegaly? (0:18)
- What are the challenges of producing a somatostatin based oral therapy? (1:41)
- What did the CHIASMA OPTIMAL study show us about the efficacy and safety of oral octreotide capsules compared with injectable somatostatin analogs in acromegaly? (2:46)
- What were the findings of the recent open label extension study of CHIASMA OPTIMAL? (4:24)
- Which patients are most likely to respond to oral octreotide capsules and in whom are they contraindicated? (6:13)
Disclosures: Dr Susan Samson was a site PI and steering chair for the Chiasma OPTIMAL trial.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ENDO 2021 (Virtual).
